Dec 12,2023

Digitised pathology resource will speed HIV cancer R&D

The National Institutes of Health (NIH)-funded AIDS and Cancer Specimen Resource (ACSR) is using Proscia’s Concentriq for Research software to dramatically reduce the time it takes to make this real-world data available to researchers from “hours to days”, making it a near real-time resource for researchers, say the partners. ACSR’s repository includes specimens – often on glass microscope slides – that have been collected over decades from people with HIV who have been diagnosed with a wide spectrum of conditions and diseases, particularly cancers, both before and after treatment with antiretroviral therapy (ART). Proscia’s artificial intelligence-powered software is already being applied to projects looking at cancers that develop as a consequence of immune suppression in people living with HIV, and today the ACSR has announced a rare melanoma tissue repository on Concentriq for Research that will be accompanied early next year with a corresponding tumour tissue microarray.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 11,2023 TOP STORY

ConcertAI to Acquire CancerLinQ to Build the Leading Healthcare Learning and Research Network in Oncology

ConcertAI announced the acquisition of CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO). In conjunction with the acquisition, ASCO will maintain a multi-year cooperation agreement with CancerLinQ. Building on CancerLinQ's mission when launched by ASCO in 2013, this new venture will enhance and expand CancerLinQ's use of real-world data, analytics, next-generation AI, and other technologies to improve cancer care and speed clinical research. With a network of more than 100 cancer centers and oncology practices, 10 EMR system integrations, and data from nearly seven million patient records, CancerLinQ empowers oncology care teams and researchers with technology and data innovations to improve care and accelerate cancer research. ConcertAI will collaborate with ASCO to substantially enhance the value of CancerLinQ for oncology practices and their patients making clinical trials participation more accessible and less burdensome through ConcertAI's Digital Access to Clinical Trial (DACT) platform, bolstering SmartLinQ™ to include new data sources alongside the robust clinical data currently available, and developing more robust clinical decision support within SmartLinQ.

COLLABORATION MERGERS & ACQUISITION

#product & service

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 07,2023

Daman set to launch app geared to young cancer patients

Danish digital health firm Daman is preparing to debut its cancer app for young patients in 2024. The product, known as Kræftværket – or the "Cancer Forge" in English – aims to help patients cope with their diagnosis, while alleviating loneliness. Kræftværket, tailored for teenagers and young adults in cancer treatment, offers a comprehensive suite of features including symptom tracking, access to health information, and a supportive online community. The app will be implemented across all five regions in Denmark. Professor Helle Pappot from Rigshospitalet, instrumental in the app's development, highlights its impact: "The solution has been a crucial tool in empowering patients to manage their disease, and thorough our clinical research we have been able to document the positive impact on patient’s quality of life."

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 07,2023

AI May Spare Breast Cancer Patients Unnecessary Treatments

A new AI tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using a more precise method of predicting their outcomes, reports a new Northwestern Medicine study published in Nature Medicine. The study was conducted in collaboration with the American Cancer Society (ACS) which created a unique dataset of breast cancer patients through their Cancer Prevention Studies. This dataset has representation of patients from over 423 U.S. counties, many who received a diagnosis or care at community medical centers. In this collaboration, Northwestern developed the AI software while scientists at the ACS and National Cancer Institute provided expertise on breast cancer epidemiology and clinical outcomes. To train the AI model, scientists required hundreds of thousands of human-generated annotations of cells and tissue structures within digital images of patient tissues. To achieve this, they created an international network of medical students and pathologists across several continents. The AI system was desined to analyze 26 different properties of a patient’s breast tissue to generate an overall prognostic score. The system also generates individual scores for the cancer, immune and stromal cells to explain the overall score to the pathologist. The AI tool was able to identify breast cancer patients who are currently classified as high or intermediate risk but who become long-term survivors. That means the duration or intensity of their chemotherapy could be reduced. Next the scientists will evaluate this model prospectively to validate it for clinical use.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 08,2023

Digital health coaching program for breast cancer did not improve patient-reported outcomes

A novel digital health coaching program did not improve patient-reported outcomes among individuals with active breast cancer, according to study results presented at San Antonio Breast Cancer Symposium. The researchers sought to evaluate the effect of a digital health coaching program on patient-reported outcomes, including global health, symptom burden, quality of life, health care utilization and financial toxicity. The analysis included 254 English-speaking adult women undergoing active treatment for breast cancer. Researchers randomly assigned 127 women to usual care. They assigned the other 127 to a 6-month digital health coaching program, which included weekly telephone calls from a health adviser; unlimited patient-initiated communication via phone, text or email; and digital delivery of additional health-behavior content. Results showed no significant improvement in physical patient-reported outcome scores at 3 months or 6 months among women assigned the digital intervention vs. usual care. Researchers reported similar results for mental patient-reported outcome scores at 3 months and 6 months. They also reported potential reasons for failure to detect a treatment effect for digital health coaching, including the ineffectiveness of digital health coaching on the selected outcomes, the low strength of the intervention, the variation in uptake of digital health coaching in the intervention group, heterogeneity of the sample and the potential that the study was underpowered due to COVID-19 restrictions that affected enrollment.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 29,2023

Qure to Boost Global Healthcare with Advanced AI Integration

Qure.ai announces its collaboration with GE HealthCare. This collaboration aims to bringing the power of AI-driven healthcare to medical professionals and patients alike. Qure's AI solution, known for its seamless integration and improving diagnostic capabilities of radiology departments, will comprehensively cater to a range of care areas including stroke, lung cancer, early indications of heart failure, and intensive care and emergency care cases. Qure's AI, seamlessly integrated into the GE HealthCare’s App Orchestrator platform, promises streamlined workflows and optimized resource utilization. The platform will enable healthcare providers to access Qure’s flagship products; qXR – AI enabled chest X-ray solution and qER – AI enabled head CT solution for use cases like ICU settings, and preliminary reporting of normal-abnormal reports with increased speed and accuracy.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 06,2023 TOP STORY

NHS Greater Glasgow and Clyde deploys multi-site AI for earlier detection of lung cancer

A digital health collaboration consisting of The Scottish Government, University of Glasgow, Qure.ai and NHS Greater Glasgow and Clyde (NHSGGC) is rolling out the AI-powered chest X-ray reporting solution, qXR, across Glasgow, for approximately 70,000 chest X-rays per year. The aim is to detect lung cancer earlier to improve patient survival. It is part of a national coordinated evaluation of Artificial Intelligence (AI) in radiology to improve patient outcomes, plus prove clinical and cost effectiveness. qXR is being supported by the University of Glasgow’s Digital Health Validation Lab, part of the Living Laboratory for Precision Medicine, providing academic leadership and support to deliver the trial alongside NHSGGC and Qure.ai.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 05,2023

RadNet Unveils DeepHealth, a Pioneering AI-Powered Health Informatics Portfolio

RadNet, Inc, a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and parent company of Aidence since 2022, announces the launch of DeepHealth, a health informatics portfolio designed to drive efficiency and transform radiology’s role in healthcare. DeepHealth introduces a pioneering cloud-native operating system (OS), powered by clinical AI, that improves disease detection and that leverages operational generative AI, to efficiently orchestrate patient engagement and care delivery. The newly launched portfolio builds on the strengths of RadNet’s existing digital health businesses and products, including eRAD Radiology Information and Image Management Systems, Aidence lung AI, Quantib prostate AI and DeepHealth breast AI. At the heart of the DeepHealth portfolio is DeepHealth OS, a cloud-native workflow engine intended to integrate data across an enterprise with API-based modules and to offer personalized workflow applications for a multitude of roles.

PRODUCT

#ai/software

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Dec 06,2023 TOP STORY

Jasper Health Unveils Medicare Focused Cancer Care Navigation Leveraging AI, Aligned with New Reimbursement Codes

Jasper Health launched a Cancer Care Navigation and Supportive Care Solution, aimed at transforming oncology navigation support for Medicare populations, in sync with CMS’s recent announcement to reimburse Health-Related Social Needs. “Patient Navigators serve as the guiding light for individuals navigating the intricate landscape of a cancer diagnosis and treatment. In this new reimbursable model, we will be offering high-touch, wrap-around navigation virtually. Our specialty-trained Cancer Care Navigators directly match with affected individuals, providing empathetic guidance and tailored resources every step of the way,” says Holly Spinks, Chief Clinical & Compliance Officer at Jasper Health. Jasper currently offers seniors a multi-channel navigation service that includes a digital planner and dedicated Care Navigator. To enable cancer navigation at scale, this is paired with Jasper Compass, the AI-driven Cancer Care Management Platform, which allows targeted, efficient, and personalized approach to managing patient care, helping the Navigators optimize resources and interventions based on individual patient needs, ultimately leading to improved outcomes. “Jasper Compass is now available for payors, health systems, and provider partners. This fully customizable and white-labeled platform empowers care professionals to enhance overall outcomes by improving the coordination of patient care,” stated Spinks.

PRODUCT

#rpm

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 04,2023 TOP STORY

Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate

Absci Corporation, a leader in generative AI antibody discovery, announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed antibody against an oncology target. This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate. Absci will contribute its generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales, mounting up to $247 million USD. Today’s agreement comes on the heels of Absci’s publication on the design and validation of de novo antibodies using Absci’s state-of-the-art 'zero-shot' generative AI model and follows additional collaborations with leading biopharmaceutical, healthcare and technology organizations.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY